COVID-19 Archives
Vanderbilt recruiting children to study allergic responses to COVID-19 mRNA vaccines
Jan. 24, 2022—Vanderbilt is conducting a clinical trial to determine risk and mechanisms of allergic reactions to COVID-19 Pfizer-BioNTech mRNA vaccine among children.
Omicron evades some but not all monoclonal antibodies: study
Jan. 20, 2022—A new study found that several, but not all, of the human monoclonal antibodies used clinically to prevent patients from becoming severely ill from COVID-19 may not be protective against the Omicron variant now sweeping across the United States.
Grant boosts vaccine effectiveness research
Jan. 6, 2022—by Nancy Humphrey Investigators at Vanderbilt University Medical Center have received a $10.7 million research award from the Centers for Disease Control and Prevention (CDC) to continue the IVY Research Network, originally created in 2019 to look at how well flu vaccines work at preventing severe flu illness, and expanded in 2021 to enroll patients...
Study of fully vaccinated patients with cancer who had breakthrough COVID-19 shows 13% mortality rate
Dec. 24, 2021—New research finds that fully vaccinated patients with cancer who had breakthrough COVID-19 infections remained at high risk for hospitalization and death.
Patient receives antibodies discovered at Vanderbilt to prevent COVID-19 illness
Dec. 23, 2021—On Dec. 22, Caroline Davis of Nashville became the first patient at Vanderbilt University Medical Center to receive injections of a new antibody combination to protect her from COVID-19.
“Supermeres” may carry clues to cancer, Alzheimer’s disease and COVID-19
Dec. 10, 2021—Vanderbilt researchers have discovered a nanoparticle released from cells, called a “supermere,” which contains enzymes, proteins and RNA associated with multiple cancers, cardiovascular disease, Alzheimer’s disease and even COVID-19.
Antibodies discovered at Vanderbilt for prevention of COVID-19 granted FDA emergency use authorization
Dec. 9, 2021—The U.S. Food and Drug Administration granted emergency use authorization (EUA) to the global biopharmaceutical company AstraZeneca for a long-acting antibody combination which protects against COVID-19, discovered last year at Vanderbilt University Medical Center.
Weigh risks, plan ahead prior to gathering for the holidays
Dec. 8, 2021—Vanderbilt University Medical Center infectious disease experts advise this is the season to think very wisely about planned get-togethers.
Surveys show VUMC patients value immediate online access to test results
Dec. 2, 2021— by Paul Govern Vanderbilt University Medical Center patients are overwhelmingly in favor of having immediate electronic access to their clinical test results, recent surveys show. A federal rule in effect since April 5 was designed in part to ensure that patients are given electronic access to their health information upon their request and at no cost, including, with very few exceptions,...
Long-acting antibody combo developed at VUMC reduces COVID-19 risk and symptoms
Dec. 2, 2021— by Bill Snyder The global biopharmaceutical company AstraZeneca announced more good news about its long-acting combination of two monoclonal antibodies against COVID-19 that were discovered at Vanderbilt University Medical Center. In a prevention trial, one prophylactic, intramuscular injection of the antibody combination, called AZD7442, reduced the risk of symptoms occurring after exposure to the...
VUMC researchers involved in developing Moderna’s COVID-19 vaccine featured in Smithsonian exhibit
Nov. 23, 2021—Researchers at Vanderbilt University Medical Center who contributed to the development of Moderna’s COVID-19 vaccine are featured in a new exhibit at the Smithsonian Institution in Washington, D.C.
Seven from VUMC among most highly cited researchers
Nov. 18, 2021—Seven Vanderbilt faculty members have made this year’s list of scientists whose papers have been cited most frequently by other researchers.
